Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + GEMOX + sintilimab first-line study in advanced biliary tract cancer
ChiCTR2400093090Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine, gemcitabine, oxaliplatin and sintilimab in biliary cancer, sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Safety and Objective response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
decitabinegemcitabineoxaliplatinsintilimab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2400093090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093090.